| Relevance/rationale of the indicator (resp. why the indicator was chosen to measure the target and how it is suitable for these purposes) |
Success of comprehensive oncological care, including the success of early detection programs, availability and quality of anticancer treatment. |
| Target value of the indicator and its evaluation |
|
| Definition |
To assess the survival of cancer patients, the so-called relative survival is used, which is defined as the ratio of overall survival and so-called expected survival. Expected survival expresses mortality in the general population, which corresponds to the observed group of patients by age, sex and year of diagnosis. The aim of calculating relative survival is to filter out the effect of mortality associated with diseases other than the observed malignancies. The so-called time period analysis, usually five years, is used for evaluation. |
| Measuring unit |
% |
| Indicator disaggregation |
By oncological diagnosis
By stages |
| Reference period (resp. the period to which the indicator relates) |
5 years |
| Related geographical area |
CZ (NUTS 0) |
| Comment |
Reported 5-year survival values for individual diagnoses are standardized for patient age and representation of clinical stages. The 5-year survival values for individual stages are age-standardized.
Diagnosis C61: combined stages I + II. |
